Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 11,740 shares at $113.77 ($1.4M) on 2021-02-05, disclosed to the SEC on 2021-02-09.
Seasonal sale ($1.4M) by Chief Business Development Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $113.77 | 703 | $80K | 5.9% |
| 2 | $113.77 | 703 | $80K | 5.9% |
| 3 | $114.09 | 1,974 | $225K | 16.6% |
| 4 | $114.09 | 1,974 | $225K | 16.6% |
| 5 | $116.83 | 1,623 | $190K | 14.0% |
| 6 | $116.83 | 1,000 |
| $117K |
| 8.6% |
| 7 | $116.83 | 1,623 | $190K | 14.0% |
| 8 | $116.89 | 1,070 | $125K | 9.2% |
| 9 | $116.89 | 1,070 | $125K | 9.2% |
| Total | $115.55 avg | 11,740 | $1.4M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |